Insider Trading Activity Selecta Biosciences Inc. (NASDAQ:SELB) – insider Sold 4,723 shares of Stock

ME Staff

8 years ago

Insider Trading Activity For Selecta Biosciences Inc. (NASDAQ:SELB)

Peter Keller , insider of Selecta Biosciences Inc. (NASDAQ:SELB) reportedly Sold 4,723 shares of the company’s stock at an average price of 18.58 for a total transaction amount of $87,753.34 SEC Form

Insider Trading History For Selecta Biosciences Inc. (NASDAQ:SELB)

On 6/27/2016 Nanodimension Management Ltd, Major Shareholder, bought 385,000 with an average share price of $14.00 per share and the total transaction amounting to $5,390,000.00.

On 6/27/2016 Amir Nashat, Director, bought 150,000 with an average share price of $14.00 per share and the total transaction amounting to $2,100,000.00.

On 12/19/2016 Peter Keller, insider, sold 4,723 with an average share price of $18.58 per share and the total transaction amounting to $87,753.34.

Analyst Ratings For Selecta Biosciences Inc. (NASDAQ:SELB)
These are 3 Buy RatingsThe current consensus rating for Selecta Biosciences Inc. (NASDAQ:SELB) is Buy (Score: 3.00) with a consensus target price of $28.33 , a potential (55.76% upside)

Analyst Ratings History For Selecta Biosciences Inc. (NASDAQ:SELB)

On 7/18/2016 Needham & Company LLC Initiated Coverage of rating Buy with a price target of $28.00
On 12/6/2016 Canaccord Genuity Set Price Target of rating Buy with a price target of $25.00
On 12/8/2016 Stifel Nicolaus Reiterated Rating Buy with a price target of $23.00 to $32.00

About Selecta Biosciences Inc. (NASDAQ:SELB)
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. Its SVP technology has a range of applications to both manage biologic drugs and enable therapies. It offers product candidates in programs, including SVP for immune tolerance and SVP for immune stimulation. Its SVP for immune stimulation includes Smoking cessation and relapse prevention (SEL-070), and human papillomavirus (HPV)-associated cancer (SEL-701).

Recent Trading Activity for Selecta Biosciences Inc. (NASDAQ:SELB)
Shares of Selecta Biosciences Inc. closed the previous trading session at 18.19 up +0.29 1.62% with 164,799 shares trading hands.